Illumina, Inc. $ILMN Stock Holdings Lowered by Rhumbline Advisers

Rhumbline Advisers lessened its position in Illumina, Inc. (NASDAQ:ILMN) by 2.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 618,663 shares of the life sciences company’s stock after selling 13,289 shares during the period. Rhumbline Advisers owned approximately 0.40% of Illumina worth $58,754,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ILMN. WCM Investment Management LLC grew its position in Illumina by 5.9% in the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock worth $419,585,000 after purchasing an additional 247,460 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Illumina by 1.9% during the second quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after buying an additional 78,317 shares during the period. AQR Capital Management LLC grew its holdings in Illumina by 55.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after buying an additional 1,174,295 shares in the last quarter. Geode Capital Management LLC increased its position in Illumina by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock valued at $272,921,000 after acquiring an additional 21,342 shares during the period. Finally, Bank of America Corp DE raised its stake in Illumina by 1.9% during the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after acquiring an additional 35,167 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on ILMN. UBS Group reissued a “neutral” rating and issued a $135.00 price target on shares of Illumina in a research note on Friday, February 6th. Canaccord Genuity Group increased their target price on shares of Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research report on Monday, January 26th. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Stifel Nicolaus raised their price objective on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $129.17.

Insider Activity at Illumina

In other news, insider Scott M. Davies sold 323 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.60% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $114.44 on Friday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average of $137.54 and a two-hundred day moving average of $116.47. The company has a market capitalization of $17.49 billion, a price-to-earnings ratio of 21.00, a PEG ratio of 2.23 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the previous year, the firm earned $0.95 EPS. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.